First-in-Human Trial Shows Synthetic Immune Cell Activator IMM60 Is Safe in Advanced Cancer
A first-in-human phase I trial found that the liposomal iNKT cell agonist IMM60, given alone or with pembrolizumab, was well ...
Tag: checkpoint inhibitor
Immunotherapy Boost for Bile Duct Cancer Survival Holds Firm After Three Years
Three-year follow-up of the phase 3 KEYNOTE-966 trial confirms that adding pembrolizumab to gemcitabine and cisplatin chemotherapy maintains a durable ...
Two Approved Companion Diagnostics Validate Pembrolizumab Eligibility Across dMMR/MSI-H Tumors
Bridging studies confirm that the Ventana MMR RxDx Panel and FoundationOne CDx reliably identify dMMR/MSI-H tumor patients likely to respond ...
Immunotherapy Brings Three-Year Survival in Rare, Usually Fatal Lung Vascular Cancer Syndrome
A Japanese case report describes more than three years of progression-free survival in pulmonary tumour thrombotic microangiopathy after prompt nivolumab ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!